

Treatment-Emergent Adverse Events with Outcome of Death by System Organ Class and Preferred Term
Safety Set

System Organ Class Preferred Term	Placebo (N=100)			Nangibotide 1.0 mg/kg/h (N=119)			Total (N=219)		
	n	(%)	[E]	n	(%)	[E]	n	(%)	[E]
TOTAL NUMBER OF TREATMENT-EMERGENT ADVERSE EVENTS WITH OUTCOME OF DEATH	27			19			46		
NUMBER OF PATIENTS WITH AT LEAST ONE TREATMENT-EMERGENT ADVERSE EVENT WITH OUTCOME OF DEATH	27	(27.0)		19	(16.0)		46	(21.0)	
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	13	(13.0)	[13]	9	(7.6)	[9]	22	(10.0)	[22]
ACUTE RESPIRATORY DISTRESS SYNDROME	1	(1.0)	[1]	1	(0.8)	[1]	2	(0.9)	[2]
ACUTE RESPIRATORY FAILURE	1	(1.0)	[1]	0			1	(0.5)	[1]
HAEMOTHORAX	0			1	(0.8)	[1]	1	(0.5)	[1]
HYPOXIA	4	(4.0)	[4]	3	(2.5)	[3]	7	(3.2)	[7]
PULMONARY EMBOLISM	0			1	(0.8)	[1]	1	(0.5)	[1]
RESPIRATORY DISTRESS	0			2	(1.7)	[2]	2	(0.9)	[2]
RESPIRATORY FAILURE	7	(7.0)	[7]	1	(0.8)	[1]	8	(3.7)	[8]
INFECTIONS AND INFESTATIONS	6	(6.0)	[6]	6	(5.0)	[6]	12	(5.5)	[12]
COVID-19	1	(1.0)	[1]	1	(0.8)	[1]	2	(0.9)	[2]
SEPTIC SHOCK	5	(5.0)	[5]	5	(4.2)	[5]	10	(4.6)	[10]
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	6	(6.0)	[6]	0			6	(2.7)	[6]
MULTIPLE ORGAN DYSFUNCTION SYNDROME	6	(6.0)	[6]	0			6	(2.7)	[6]
NERVOUS SYSTEM DISORDERS	1	(1.0)	[1]	2	(1.7)	[2]	3	(1.4)	[3]
BRAIN INJURY	0			1	(0.8)	[1]	1	(0.5)	[1]
CEREBRAL HAEMORRHAGE	0			1	(0.8)	[1]	1	(0.5)	[1]
HAEMORRHAGIC STROKE	1	(1.0)	[1]	0			1	(0.5)	[1]

At each level of patient summarization, a patient is counted once if the patient reported one or more events. [E] represents the number of events at each level of summarization. Adverse Events were coded using MedDRA, Version 23.0.

Source Data: Listing 11

Treatment-Emergent Adverse Events with Outcome of Death by System Organ Class and Preferred Term
Safety Set

System Organ Class Preferred Term	Placebo (N=100)			Nangibotide 1.0 mg/kg/h (N=119)			Total (N=219)		
	n	(%)	[E]	n	(%)	[E]	n	(%)	[E]
VASCULAR DISORDERS	1	(1.0)	[1]	2	(1.7)	[2]	3	(1.4)	[3]
PERIPHERAL ISCHAEMIA	0			1	(0.8)	[1]	1	(0.5)	[1]
SHOCK	1	(1.0)	[1]	1	(0.8)	[1]	2	(0.9)	[2]

At each level of patient summarization, a patient is counted once if the patient reported one or more events. [E] represents the number of events at each level of summarization. Adverse Events were coded using MedDRA, Version 23.0.
Source Data: Listing 11

Treatment-Emergent Adverse Events with Outcome of Death by System Organ Class and Preferred Term
Safety Set Patients with Baseline sTREM-1 Level Above or Equal to the Median

System Organ Class Preferred Term	Placebo (N=55)			Nangibotide 1.0 mg/kg/h (N=54)			Total (N=109)		
	n	(%)	[E]	n	(%)	[E]	n	(%)	[E]
TOTAL NUMBER OF TREATMENT-EMERGENT ADVERSE EVENTS WITH OUTCOME OF DEATH	22			13			35		
NUMBER OF PATIENTS WITH AT LEAST ONE TREATMENT-EMERGENT ADVERSE EVENT WITH OUTCOME OF DEATH	22	(40.0)		13	(24.1)		35	(32.1)	
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	11	(20.0)	[11]	7	(13.0)	[7]	18	(16.5)	[18]
ACUTE RESPIRATORY DISTRESS SYNDROME	1	(1.8)	[1]	1	(1.9)	[1]	2	(1.8)	[2]
ACUTE RESPIRATORY FAILURE	1	(1.8)	[1]	0			1	(0.9)	[1]
HYPOXIA	3	(5.5)	[3]	3	(5.6)	[3]	6	(5.5)	[6]
PULMONARY EMBOLISM	0			1	(1.9)	[1]	1	(0.9)	[1]
RESPIRATORY DISTRESS	0			2	(3.7)	[2]	2	(1.8)	[2]
RESPIRATORY FAILURE	6	(10.9)	[6]	0			6	(5.5)	[6]
INFECTIONS AND INFESTATIONS	6	(10.9)	[6]	3	(5.6)	[3]	9	(8.3)	[9]
COVID-19	1	(1.8)	[1]	1	(1.9)	[1]	2	(1.8)	[2]
SEPTIC SHOCK	5	(9.1)	[5]	2	(3.7)	[2]	7	(6.4)	[7]
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	4	(7.3)	[4]	0			4	(3.7)	[4]
MULTIPLE ORGAN DYSFUNCTION SYNDROME	4	(7.3)	[4]	0			4	(3.7)	[4]
NERVOUS SYSTEM DISORDERS	1	(1.8)	[1]	2	(3.7)	[2]	3	(2.8)	[3]
BRAIN INJURY	0			1	(1.9)	[1]	1	(0.9)	[1]
CEREBRAL HAEMORRHAGE	0			1	(1.9)	[1]	1	(0.9)	[1]
HAEMORRHAGIC STROKE	1	(1.8)	[1]	0			1	(0.9)	[1]

At each level of patient summarization, a patient is counted once if the patient reported one or more events. [E] represents the number of events at each level of summarization. Adverse Events were coded using MedDRA, Version 23.0.

Source Data: Listing 11

Treatment-Emergent Adverse Events with Outcome of Death by System Organ Class and Preferred Term
Safety Set Patients with Baseline sTREM-1 Level Above or Equal to the Median

System Organ Class Preferred Term	Placebo (N=55)	Nangibotide 1.0 mg/kg/h (N=54)		Total (N=109)
	n (%) [E]	n (%) [E]		n (%) [E]
VASCULAR DISORDERS	0	1 (1.9)	[1]	1 (0.9) [1]
PERIPHERAL ISCHAEMIA	0	1 (1.9)	[1]	1 (0.9) [1]

At each level of patient summarization, a patient is counted once if the patient reported one or more events. [E] represents the number of events at each level of summarization. Adverse Events were coded using MedDRA, Version 23.0.
Source Data: Listing 11